Linda Luong, MD
Family Medicine · Winchester, VANPI 1689647257
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 43.2% of the total. Reporting peaked in 2022 at $235 and has fallen 89.5% since, to $25 in 2025.
Across 55 payments — averaging $13.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$316
- Novo Nordisk$143
- AstraZeneca$89
- Abbott$62
- Lilly USA, LLC$55
- Sanofi Pasteur Inc.$24
- plus $44 from 3 others
What the payments were for
- Food & beverage$732100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $316 |
| Novo Nordisk | 10 | $143 |
| AstraZeneca | 6 | $89 |
| Abbott | 3 | $62 |
| Lilly USA, LLC | 3 | $55 |
| Sanofi Pasteur Inc. | 2 | $24 |
| Boehringer Ingelheim | 1 | $15 |
| Amgen | 1 | $15 |
| Pfizer | 1 | $14 |
How this compares
$732 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 33 | $46,112 |
| OzempicSemaglutide | 33 | $45,757 |
| TrulicityDulaglutide | 32 | $45,269 |
| RybelsusSemaglutide | 18 | $22,569 |
| MounjaroTirzepatide | 20 | $19,095 |
| EliquisApixaban | 15 | $18,756 |
| Spiriva RespimatTiotropium Bromide | 24 | $15,988 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $7,079 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,835 |
| Rosuvastatin Calcium | 126 | $2,853 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,376 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,283 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,975 |
| Estradiol | 18 | $1,891 |
| Famotidine | 107 | $1,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $143 | $68,32651 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $55 | $64,36452 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $15 | $62,10057 claims |
| PfizerEliquis | $14 | $18,75615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Winchester
- Jordan TranWinchester$42K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.